Diabetic foot infection: Difference between revisions
From IDWiki
No edit summary |
m (Text replacement - " species]]" to "]]") |
||
| (6 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
== |
==Background== |
||
===Microbiology=== |
|||
* Typically involve a combination of ''Staphylococci'', ''Streptococci'', Proteobacteria (Gram-negative bacterial genus that includes enterics), and anaerobes |
|||
* Anaerobes are more likely to be involved in deeper, more chronic ulcers |
|||
*Typically polymicrobial, including: |
|||
== Further Reading == |
|||
**[[Staphylococcus aureus]], which is by far the most common cause of monomicrobial infections |
|||
**[[Coagulase-negative staphylococci]] |
|||
**[[Streptococcus]] |
|||
**[[Enterococcus]] |
|||
**[[Enterobacteriaceae]] |
|||
**[[Pseudomonas aeruginosa]] |
|||
**[[Anaerobes]], including [[Bacteroides fragilis]] |
|||
*Anaerobes are more likely to be involved in deeper, more chronic ulcers |
|||
==Diagnosis== |
|||
* [https://doi.org/10.2337/db12-0771 The Neuropathic Diabetic Foot Ulcer Microbiome IsAssociated With Clinical Factors]. ''Diabetes''. 2013;62:923-930. |
|||
*Osteomyelitis should be considered in all cases of diabetic foot infection |
|||
**[[Probe-to-bone test]] should be done routinely |
|||
**Plain film X-ray can be helpful, though not sensitive |
|||
**MRI is the preferred diagnostic test, followed by bone and white cell scan |
|||
**The gold standard is still bone biopsy for histopathology and culture |
|||
==Management== |
|||
{| class="wikitable" |
|||
!Severity |
|||
!Common Pathogens |
|||
!Antibiotics |
|||
!Notes |
|||
|- |
|||
| rowspan="7" |Mild |
|||
| rowspan="5" |methicillin-susceptible [[Staphylococcus aureus]], [[Streptococcus]] |
|||
|[[dicloxacillin]] |
|||
|qid dosing and very narrow-spectrum |
|||
|- |
|||
|[[clindamycin]] |
|||
|active against MRSA but higher risk of [[CDAD]] |
|||
|- |
|||
|[[cephalexin]] |
|||
|qid dosing |
|||
|- |
|||
|[[levofloxacin]] |
|||
|not as effective against [[Staphylococcus aureus]] |
|||
|- |
|||
|[[amoxicillin-clavulanic acid]] |
|||
|broad-spectrum, includes anaerobic coverage |
|||
|- |
|||
| rowspan="2" |methicillin-resistant [[Staphylococcus aureus]] |
|||
|[[doxycycline]] |
|||
|uncertain activity against streptococci |
|||
|- |
|||
|[[TMP-SMX]] |
|||
|uncertain activity against streptococci |
|||
|- |
|||
| rowspan="13" |moderate or severe |
|||
| rowspan="9" |[[MSSA]], [[Streptococcus]], [[Enterobacteriaceae]], [[anaerobes]] |
|||
|[[levofloxacin]] |
|||
|suboptimal against MSSA |
|||
|- |
|||
|[[cefoxitin]] |
|||
| |
|||
|- |
|||
|[[ceftriaxone]] |
|||
| |
|||
|- |
|||
|[[ampicillin-sulbactam]] |
|||
| |
|||
|- |
|||
|[[moxifloxacin]] |
|||
| |
|||
|- |
|||
|[[ertapenem]] |
|||
| |
|||
|- |
|||
|[[tigecycline]] |
|||
| |
|||
|- |
|||
|[[Fluoroquinolones|fluoroquinolone]] with [[clindamycin]] |
|||
| |
|||
|- |
|||
|[[imipenem-cilastatin]] |
|||
| |
|||
|- |
|||
| rowspan="3" |MRSA |
|||
|[[linezolid]] |
|||
| |
|||
|- |
|||
|[[daptomycin]] |
|||
| |
|||
|- |
|||
|[[vancomycin]] |
|||
| |
|||
|- |
|||
|[[Pseudomonas aeruginosa]] |
|||
|[[piperacillin-tazobactam]] |
|||
| |
|||
|} |
|||
===Duration=== |
|||
{| class="wikitable" |
|||
!Site of Infection |
|||
!Severity |
|||
!Duration |
|||
|- |
|||
| rowspan="3" |soft tissue only |
|||
|mild |
|||
|1 to 2 weeks; up to 4 weeks if slow-to-resolve |
|||
|- |
|||
|moderate |
|||
|1 to 3 weeks |
|||
|- |
|||
|severe |
|||
|2 to 4 weeks |
|||
|- |
|||
| rowspan="4" |bone and joint infection |
|||
|postamputation, with no residual infection |
|||
|2 to 5 days |
|||
|- |
|||
|postamputation, with residual soft tissue infection |
|||
|1 to 3 weeks |
|||
|- |
|||
|postamputation, with residual bone infection |
|||
|4 to 6 weeks |
|||
|- |
|||
|no surgery |
|||
|≥3 months |
|||
|} |
|||
*Osteomyelitis |
|||
**Traditionally, 6 weeks of parenteral therapy |
|||
**May be able to shorten to 3 weeks if adequately debrided, based on more recent evidence[[CiteRef::gariani2020th]] |
|||
==Further Reading== |
|||
*[https://doi.org/10.2337/db12-0771 The Neuropathic Diabetic Foot Ulcer Microbiome IsAssociated With Clinical Factors]. ''Diabetes''. 2013;62:923-930. |
|||
[[Category:Skin and soft tissue infections]] |
[[Category:Skin and soft tissue infections]] |
||
Latest revision as of 04:02, 28 January 2022
Background
Microbiology
- Typically polymicrobial, including:
- Staphylococcus aureus, which is by far the most common cause of monomicrobial infections
- Coagulase-negative staphylococci
- Streptococcus
- Enterococcus
- Enterobacteriaceae
- Pseudomonas aeruginosa
- Anaerobes, including Bacteroides fragilis
- Anaerobes are more likely to be involved in deeper, more chronic ulcers
Diagnosis
- Osteomyelitis should be considered in all cases of diabetic foot infection
- Probe-to-bone test should be done routinely
- Plain film X-ray can be helpful, though not sensitive
- MRI is the preferred diagnostic test, followed by bone and white cell scan
- The gold standard is still bone biopsy for histopathology and culture
Management
| Severity | Common Pathogens | Antibiotics | Notes |
|---|---|---|---|
| Mild | methicillin-susceptible Staphylococcus aureus, Streptococcus | dicloxacillin | qid dosing and very narrow-spectrum |
| clindamycin | active against MRSA but higher risk of CDAD | ||
| cephalexin | qid dosing | ||
| levofloxacin | not as effective against Staphylococcus aureus | ||
| amoxicillin-clavulanic acid | broad-spectrum, includes anaerobic coverage | ||
| methicillin-resistant Staphylococcus aureus | doxycycline | uncertain activity against streptococci | |
| TMP-SMX | uncertain activity against streptococci | ||
| moderate or severe | MSSA, Streptococcus, Enterobacteriaceae, anaerobes | levofloxacin | suboptimal against MSSA |
| cefoxitin | |||
| ceftriaxone | |||
| ampicillin-sulbactam | |||
| moxifloxacin | |||
| ertapenem | |||
| tigecycline | |||
| fluoroquinolone with clindamycin | |||
| imipenem-cilastatin | |||
| MRSA | linezolid | ||
| daptomycin | |||
| vancomycin | |||
| Pseudomonas aeruginosa | piperacillin-tazobactam |
Duration
| Site of Infection | Severity | Duration |
|---|---|---|
| soft tissue only | mild | 1 to 2 weeks; up to 4 weeks if slow-to-resolve |
| moderate | 1 to 3 weeks | |
| severe | 2 to 4 weeks | |
| bone and joint infection | postamputation, with no residual infection | 2 to 5 days |
| postamputation, with residual soft tissue infection | 1 to 3 weeks | |
| postamputation, with residual bone infection | 4 to 6 weeks | |
| no surgery | ≥3 months |
- Osteomyelitis
- Traditionally, 6 weeks of parenteral therapy
- May be able to shorten to 3 weeks if adequately debrided, based on more recent evidence1
Further Reading
- The Neuropathic Diabetic Foot Ulcer Microbiome IsAssociated With Clinical Factors. Diabetes. 2013;62:923-930.
References
- ^ Karim Gariani, Truong-Thanh Pham, Benjamin Kressmann, François R Jornayvaz, Giacomo Gastaldi, Dimitrios Stafylakis, Jacques Philippe, Benjamin A Lipsky, İlker Uçkay. Three versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: A prospective, randomized, non-inferiority pilot trial. Clinical Infectious Diseases. 2020. doi:10.1093/cid/ciaa1758.
